CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

21-903

MICROBIOLOGY REVIEW(S)

DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF PHARMACEUTICAL SCIENCES
NEW DRUG MICROBIOLOGY STAFF

MEMORANDUM

Date: 27 February 2006

TO: File

FROM: Robert J. Mello, Ph.D., Reviewer, New Drug Microbiology Staff

Cc: David Hussong, Ph.D., Associate Director, New Drug Microbiology Staff
J.L. McVey, Microbiology Team Leader, New Drug Microbiology Staff
Stephen E. Langille, Ph.D., Senior Reviewer, New Drug Microbiology Staff

SUBJECT: Review of Amendment: NDA 21-903/N000 BI (filename N021903R2.doc)

Executive Summary

This review covers an amendment to NDA 21-903/N000 BI.

The above amendment (letter dated 13 FEB 2006, Stamp Date 16 FEB 2006) corresponds to the original NDA carrying the letter date 30 AUG 2005. The amendment responds to this reviewer's questions regarding the drug product D-value report and also the sterility testing method used by the contract manufacturing facility. The identical information had been presented in an email transmission and also a fax received and dated 13 FEB 2006. It was found to be acceptable and was incorporated into my original review dated 14 FEB 2006 (filename N021903R1.doc).

Conclusion:

The submission is recommended for approval from a microbiological product quality standpoint.

END

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Robert Mello
2/28/2006 08:44:49 AM
MICROBIOLOGIST

Approved, microbiology product quality

Stephen Langille
2/28/2006 08:52:58 AM
MICROBIOLOGIST

Product Quality Microbiology Review

14 FEB 2006

NDA: 21-903/N000-BC

Drug Product Name
Proprietary: Neoprofen
Non-proprietary: Ibuprofen-L-Lysine

Drug Product Priority Classification: P

Review Number: 1

Dates of Submission(s) Covered by this Review

Letter	Stamp	Consult Sent	Assigned to Reviewer
30 AUG 2005	01 SEP 2005	06 June 2005	14 JULY 2005
12 JAN 2006	13 Jan 2006	N/A	N/A

Applicant/Sponsor
Name: Farmacon-IL, LLC.
Address: 1071 Post Road East
Westport, CT 06880-5361
Representative: Laszlo L. Darko, Ph.D.
Telephone: 203-22208801

Name of Reviewer: Robert J. Mello, Ph.D.

Conclusion: The application is recommended for approval from a microbiology product quality standpoint.

Product Quality Microbiology Data Sheet

A. 1. **TYPE OF SUBMISSION:** Original NDA

2. **SUBMISSION PROVIDES FOR:** New drug product

3. **MANUFACTURING SITE:** (Drug Product)

[redacted]

4. **DOSAGE FORM, ROUTE OF ADMINISTRATION AND STRENGTH/POTENCY:** Sterile, injectable; Intravenous; 10 mg/ml, 2ml packaged in clear glass vials

5. **METHOD(S) OF STERILIZATION:** [redacted]

6. **PHARMACOLOGICAL CATEGORY:** Cardio-Renal drug. Early treatment of patent ductus arteriosus in premature neonates.

B. **SUPPORTING/RELATED DOCUMENTS:**

- DMF review No. 15, 25-APR-2005, J. Metcalf, for the following:
  - [redacted] Building and facilities
  - Environmental monitoring program supporting [redacted]
- DMF reviews No. 12, 20 NOV 2003, and No. 12a1, 12 FEB 2004, Marla Stevens-Riley, For the following:
  - [redacted]
  - [redacted] in rooms 111, and 112, [redacted] in room 13, [redacted] in room 1122 and [redacted] in room 1151
  - Component Preparation/sterilization/depyrogenation.
- DMF review No. 17, 14 Nov 2005, Nrapendra Nath, for the following:
  - Depyrogenation of 13mm stoppers and 2ml glass vials.

C. **REMARKS:**

Reviewer comment: On 14 FEB 2006 the applicant responded to a request for additional information (dated 03 FEB 2006) concerning the submitted 2001 D-value report as well as the sterility test protocol [redacted] 2003). The information provided was found to be an adequate response to my concerns.

filename: N021903R1.doc

Executive Summary

I. Recommendations

A. Recommendation on Approvability - The application is recommended for approval from a microbiology product quality standpoint.

B. Recommendations on Phase 4 Commitments and/or Agreements, if Approvable - NA

II. Summary of Microbiology Assessments

A. Brief Description of the Manufacturing Processes that relate to Product Quality Microbiology – The drug substance, ibuprofen L-lysinate is formulated in water for injection, pH adjusted, and sterile [redacted] The drug product is then filled into previously sterilized and depyrogenated 2 ml glass vials. Following stoppering with previously sterilized stoppers, [redacted] are applied and crimped prior to [redacted]

B. Brief Description of Microbiology Deficiencies – None

C. Assessment of Risk Due to Microbiology Deficiencies – N/A

III. Administrative

A. Reviewer's Signature _____
Robert J. Mello, Ph.D.

B. Endorsement Block _____
Stephen E. Langille, Ph.D.

C. CC Block
N/A

8 Page(s) Withheld

✓ Trade Secret / Confidential

_____ Draft Labeling

_____ Deliberative Process

Withheld Track Number: Microbiology- 3

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Robert Mello
2/14/2006 01:18:53 PM
MICROBIOLOGIST

Approval recommendation, microbiology product quality

Stephen Langille
2/14/2006 01:33:22 PM
MICROBIOLOGIST